ICD-10 Code C51.0: Malignant neoplasm of labium majus

Key Takeaways

ICD-10 Code C51.0 classifies malignant neoplasm of the labium majus, a specific site within the vulvar cancer category C51

The only tabular inclusion term under C51.0 is malignant neoplasm of the Bartholin (greater vestibular) gland; melanoma of the labium majus is also reported here

When anatomical site is undocumented, use C51.9 instead; C51.0 requires explicit labium majus documentation to avoid claim downcoding

Pabau’s claims management software supports gynecologic oncology billing workflows, reducing errors in multi-code encounter submissions

ICD-10 Code C51.0 is a billable ICD-10-CM diagnosis code for malignant neoplasm of the labium majus, the outer fold of the vulva. It sits within category C51 (malignant neoplasm of vulva), and its only tabular inclusion term is malignant neoplasm of the Bartholin (greater vestibular) gland. C51.0 is valid for FY2026, effective October 1, 2025.

C51.0 classifies malignant neoplasm of the labium majus as a distinct billable entity within the broader vulvar cancer category. Assigning it requires documentation that names the labium majus or Bartholin gland as the primary site.

C51.0 sits within the ICD-10-CM classification hierarchy under Chapter 2 (Neoplasms), within the block C00-D49. More specifically, it falls under C51-C58 (Malignant neoplasms of female genital organs), and beneath the parent code C51 (Malignant neoplasm of vulva). This positional context matters for sequencing: when a patient presents for chemotherapy or radiation related to this diagnosis, C51.0 is sequenced as the underlying condition, with the encounter reason coded first per CMS ICD-10-CM coding guidelines.

The labia majora (singular: labium majus) are the outer folds of the vulva. Cancers arising from this tissue, whether squamous cell carcinoma, adenocarcinoma, or basal cell carcinoma, are classified here when the pathology confirms the labium majus as the primary site. Coders working in gynecologic oncology should note that this is a billable, valid code for FY2026 (effective October 1, 2025).

The CDC/NCHS ICD-10-CM web tool confirms C51.0 as a valid, billable code with no active Type 1 or Type 2 Excludes notes at the C51.0 level itself. Excludes notes exist at the parent C51 level and must be reviewed before submission.

What does C51.0 include? Bartholin gland and labium majus tumors

The ICD-10-CM tabular list carries a single Applicable-To (inclusion) term under C51.0, and its scope also captures other histologies that arise at this site. Misreading either point is where coding errors typically occur.

The one inclusion term listed in the tabular under C51.0 is:

• Malignant neoplasm of the Bartholin (greater vestibular) gland: The Bartholin glands are bilateral mucus-secreting glands located at the posterior introitus of the vagina, anatomically within the labium majus. Carcinomas arising from this gland (most commonly adenocarcinoma or squamous cell carcinoma) map to C51.0, confirmed by the CDC neoplasm table where Bartholin’s gland (malignant/primary) resolves to C51.0.

Beyond that single term, histology follows site here. Basal cell carcinoma arising from the skin of the labium majus is reported with C51.0 rather than a C44-series skin code, and malignant melanoma of the labium majus is also coded to C51.0: category C43 (malignant melanoma of skin) carries an Excludes2 note that routes melanoma of genital skin to C51-C52. The benign counterpart at this site is coded separately as benign neoplasm of the vulva (D28.0).

At the C51 parent level, the tabular Excludes1 note directs carcinoma in situ of the vulva to D07.1, not C51.0. Confirm the pathology report and its stated histology before code selection, since site and histology together determine whether C51.0 applies. The principle holds across all specificity-dependent codes: the tabular includes and excludes notes are binding, not advisory.

Squamous cell carcinoma is the most common histology overall, accounting for the majority of vulvar malignancies. When it arises specifically from the labium majus, C51.0 is the correct code regardless of grade or differentiation.

Related codes in the C51 ICD-10-CM category

The C51 category covers five distinct vulvar sites. Selecting the wrong subcode is one of the most common errors in gynecologic oncology coding, particularly when the tumor overlaps anatomical boundaries or the documentation is incomplete.

C51.8 applies when a malignancy overlaps two or more contiguous subsites within the vulva, and no single subsite can be identified as the point of origin. This is distinct from C51.0 with incidental extension. When a labium majus carcinoma invades adjacent labium minus tissue, C51.8 may be more appropriate than C51.0, depending on whether a dominant site can be determined from the surgical or pathology report.

C51.9 is the code of last resort for vulvar malignancy. Per the AAPC Codify ICD-10-CM reference, using an unspecified code when documentation supports specificity is a coding quality issue. Practices with robust gynecologic neoplasm coding workflows will query the provider before defaulting to C51.9.

A related code worth noting for follow-up encounters: Z85.44 (personal history of malignant neoplasm of other female genital organs) applies once a patient has completed treatment and is in surveillance. This is not used concurrently with C51.0 on active treatment encounters.

ICD-10 Code C51.0 documentation requirements

Claims for C51.0 fail or get queried most often not because the code is wrong, but because the documentation doesn’t substantiate it. Payers reviewing gynecologic oncology claims expect to find specific anatomical language in the medical record before authorizing reimbursement.

What must appear in the record

• Explicit site identification: The operative report, pathology report, or attending physician note must name the labium majus (or Bartholin gland) as the primary site of malignancy. “Vulvar cancer” alone does not support C51.0.
• Histological confirmation: A pathology report confirming malignancy (carcinoma, not just dysplasia or VIN) is required for oncology codes under C51. In situ conditions map to D07.1, not C51.0.
• Laterality documentation: ICD-10-CM does not require laterality for C51.0 (unlike breast cancer codes, for example), but noting left or right in the record is still clinically recommended and may be required by certain payers for prior authorization.
• Treatment encounter context: When coding chemotherapy or radiation encounters, the reason for the encounter is sequenced first (Z51.11 for antineoplastic chemotherapy, Z51.0 for radiation), with C51.0 as the underlying condition. Sequence errors are a common denial trigger.

Using digital clinical documentation forms that prompt providers to specify anatomical site at the point of care reduces the downstream coding burden substantially. When the encounter note already contains “labium majus” as a structured field, coders don’t need to hunt through unstructured text.

Staging and its relationship to C51.0

ICD-10-CM does not capture FIGO staging for vulvar cancer within the C51.0 code itself. Stage is recorded separately using the clinical staging fields in the medical record and, where applicable, additional Z codes or TNM descriptor fields within the EHR.

Gynecologic oncologists typically document FIGO stage I-IV in the surgical or oncology note. Coders should not infer staging from the C51.0 code or attempt to modify it based on stage.

Maintaining structured patient records that separate the pathological diagnosis from staging documentation keeps the clinical and billing workflows aligned, which matters when payers request supporting documentation for oncology authorizations.

Billing and reimbursement considerations for C51.0

C51.0 is valid for Medicare and Medicaid billing as of FY2026. However, reimbursement decisions for oncology encounters are rarely determined by the diagnosis code alone. Procedure codes, place of service, and medical necessity documentation all interact with C51.0 in ways that affect claim outcomes.

Common procedure codes paired with C51.0

Surgical excision of vulvar malignancy will typically pair C51.0 with CPT codes in the 56620-56640 range (vulvectomy procedures), depending on extent. Sentinel lymph node biopsy (CPT 38900 series) may also appear on the same claim when lymph node staging is performed. Pathological examination codes (CPT 88300-88309) are submitted by the pathology department separately.

Radiation oncology encounters for vulvar cancer use CPT codes in the 77300-77525 range, with C51.0 as the diagnosis justifying medical necessity. Chemotherapy infusion encounters bill the drug administration codes (96413, 96415) plus the chemotherapy agent HCPCS code, with C51.0 as the supporting diagnosis.

LCD and coverage considerations

Coverage for specific treatments related to C51.0 is governed by Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs) administered by CMS.

Practices should verify applicable LCDs through their MAC (Medicare Administrative Contractor) for any chemotherapy regimen or radiation protocol associated with vulvar malignancy. Quick code-lookup tools confirm that C51.0 is valid, but coverage decisions require the CMS portal or the MAC-specific LCD database.

Using claims management software that flags diagnosis-procedure mismatches before submission helps gynecologic oncology practices catch sequencing errors and missing modifiers before they reach the payer. For practices managing multiple oncology patients simultaneously, automated pre-submission edits reduce denial volume without adding manual review time. For teams comparing tools, our roundup of the best medical billing software covers these pre-submission editing features in depth.

Payer-specific requirements vary. Some commercial payers require prior authorization for vulvectomy procedures even when C51.0 is documented. Practices running sexual health clinic software benefit from built-in authorization tracking tied to the diagnosis code, tightening the handoff between clinical documentation and the billing queue.

Streamline gynecologic oncology billing with Pabau

Pabau's claims management tools help gynecologic practices catch diagnosis-procedure mismatches before submission, track authorizations, and maintain audit-ready documentation for complex oncology encounters like C51.0.

Book a demo

Crosswalks, code history, and related diagnosis codes

C51.0 has been a stable code since ICD-10-CM replaced ICD-9-CM for US billing in October 2015. Its ICD-9-CM predecessor was 184.1 (Malignant neoplasm of labium majus). No structural changes have occurred to C51.0 through FY2026. Practices transitioning legacy records or running historical analytics should map 184.1 to C51.0 for continuity.

Related diagnosis codes that commonly appear alongside C51.0 in gynecologic oncology records include:

• C77.5: Secondary malignant neoplasm of intrapelvic lymph nodes (for regional nodal metastasis)
• C78.1: Secondary malignant neoplasm of mediastinum (for distant spread, less common)
• Z85.44: Personal history of malignant neoplasm of other female genital organs (surveillance encounters)
• Z51.11: Encounter for antineoplastic chemotherapy (sequenced first on chemo encounters)
• Z51.0: Encounter for antineoplastic radiation therapy (sequenced first on radiation encounters)

When reviewing ICD-10 code documentation requirements across oncology encounter types, the sequencing rules for treatment encounters consistently require the encounter reason as the principal diagnosis, not the underlying malignancy. This is one of the most frequently misapplied guidelines in oncology billing.

For practices that need a verified code lookup, the authoritative CDC/NCHS tabular list and index entries confirm C51.0 and its crosswalks to related CPT procedure codes. Adjacent genital-organ primaries follow the same specificity rules, such as malignant neoplasm of the vagina (C52) when the primary site is vaginal rather than vulvar.

Maintaining compliance documentation for oncology code assignments, including the pathology reports and operative notes that justify the anatomical specificity of C51.0, is a necessary part of any gynecologic oncology coding audit program. Payers increasingly request supporting documentation for oncology claims as part of pre-payment review processes.

C51.0 in practice: Gynecologic oncology workflow integration

Coding accuracy for C51.0 does not begin at the billing desk. It begins at the point of care, when the clinician documents the operative findings, reviews the pathology result, and records the confirmed diagnosis in the patient’s chart.

Gynecologic oncology practices that build anatomical specificity prompts into their clinical note templates see fewer query cycles between coders and providers. When the note reads “malignant neoplasm of the labium majus confirmed by pathology dated [date]” rather than “vulvar cancer,” the coding path is unambiguous. Revenue cycle management platforms that integrate structured documentation with billing queues shorten the average time between encounter and claim submission.

For oncology billing workflows that span multiple encounter types (surgical, chemotherapy, radiation, surveillance), mapping each encounter type to its correct sequencing rule for C51.0 before the encounter is a best practice. Building a reference card for staff that maps encounter reason to principal diagnosis and secondary code reduces real-time lookup errors.

Practices using OB/GYN EMR software with built-in ICD-10 code libraries benefit from auto-suggested codes tied to procedure or diagnosis keywords, reducing the manual code lookup burden. Paired with AI clinical documentation, the site-specific language that supports C51.0 is captured as the clinician dictates. When “labium majus” appears in a structured diagnosis field, the system can surface C51.0 directly rather than requiring the coder to navigate the full C51 code family manually.

Conclusion

Vulvar cancer claims coded to C51.9 when documentation supports C51.0 are a quiet source of quality metric erosion and, in some payer environments, a denial trigger. The specificity that C51.0 provides, naming the labium majus and capturing Bartholin gland carcinoma within its scope, is only accessible when clinical documentation names the site.

Pabau’s claims management tools help gynecologic oncology practices build the documentation and pre-submission review workflows that make coding to the correct specificity level the default, not the exception. Pairing them with the right clinical documentation software keeps site-specific detail in the record from the first encounter. To see how Pabau supports complex oncology billing environments, book a demo with the team.

Continue your research

Managing gynecologic patient records across multiple encounter types? OB/GYN EMR software from Pabau is built for the documentation and scheduling complexity of gynecologic practices.

Need to strengthen pre-submission claim reviews? Claims management software flags diagnosis-procedure mismatches before they reach the payer queue.

Looking for structured forms that prompt site-specific documentation? Digital clinical documentation forms can be configured to capture anatomical specificity at the point of care.

Frequently Asked Questions